BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31285539)

  • 21. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
    Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY
    Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukaemia: analysis of patients from the Shanghai Leukaemia Co-operative Group.
    Wang W; Wang XQ; Xu XP; Lin GW
    J Int Med Res; 2010; 38(2):432-42. PubMed ID: 20515557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.
    Perry M; Bertoli S; Rocher C; Hayette S; Ducastelle S; Barraco F; Labussière-Wallet H; Salles G; Recher C; Thomas X; Paubelle E
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e545-e550. PubMed ID: 30082225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features.
    Chauhan PS; Bhushan B; Mishra AK; Singh LC; Saluja S; Verma S; Gupta DK; Mittal V; Chaudhry S; Kapur S
    Med Oncol; 2011 Jun; 28(2):544-51. PubMed ID: 20354824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The importance of FLT3 mutational analysis in acute myeloid leukemia.
    Patnaik MM
    Leuk Lymphoma; 2018 Oct; 59(10):2273-2286. PubMed ID: 29164965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low frequency and variability of FLT3 mutations in Korean patients with acute myeloid leukemia.
    Bang SM; Ahn JY; Park J; Park SH; Park J; Cho EK; Shin DB; Lee JH; Yoo SJ; Jeon IS; Kim YK; Kim HJ; Kim HN; Lee IK; Kang HJ; Shin HY; Ahn HS
    J Korean Med Sci; 2008 Oct; 23(5):833-7. PubMed ID: 18955790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FLT3 Gene Mutation Profile and Prognosis in Adult Acute Myeloid Leukemia.
    Azari-Yam A; Tavakkoly-Bazzaz J; Semnani Y; Davoudi-Dehaghani E; Ghodssi-Ghassemabadi R; Kianfar S; Saadat A; Masoudifard M; Yaghmaie M; Alimoghaddam K; Ghavamzadeh A; Zeinali S
    Clin Lab; 2016 Oct; 62(10):2011-2017. PubMed ID: 28164537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [FLT3 Mutations in Acute Myeloid Leukemia].
    Shoji T; Kida Y; Yamashita K; Ichiyama S
    Rinsho Byori; 2017 Jan; 65(1):44-51. PubMed ID: 30695511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
    Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
    Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [FLT3 mutation in patients with acute lymphoblastic leukemia and its clinical significance].
    Zhao X; Tang KJ; Tian Z; Chen LP; Mi YC; Wang JX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):522-6. PubMed ID: 19968062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FLT3-ITD and CD135 Over-Expression are Frequent Findings of Poor Survival in Adult Patients with Acute Leukemias.
    Vela-Ojeda J; Cardenas PV; Garcia-Ruiz Esparza MA; Montiel Cervantes LA; Chavez JG; Caballero AH; Majluf-Cruz A; Vega-López A; Reyes-Maldonado E
    Arch Med Res; 2021 Feb; 52(2):217-223. PubMed ID: 33109387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.
    Marensi V; Keeshan KR; MacEwan DJ
    Biochem Pharmacol; 2021 Jan; 183():114348. PubMed ID: 33242449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of FLT3-ITD and FLT3-Asp835 mutations in de novo acute myeloid leukemia: evaluation of incidence, distribution pattern, correlation with cytogenetics and characterization of internal tandem duplication from Indian population.
    Ahmad F; Mandava S; Das BR
    Cancer Invest; 2010 Jan; 28(1):63-73. PubMed ID: 19995225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
    Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prevalence and clinical significance of FLT3 mutations in acute promyelocytic leukemia].
    Xue MX; Qiu HY; Feng YF; Zhu ZL; Chang WR; Liang JY; Chen SN; Cen JN; Xue YQ; Liu YJ; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):757-61. PubMed ID: 19176014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterisation and Clinical Significance of FLT3-ITD and non-ITD in Acute Myeloid Leukaemia Patients in Kelantan, Northeast Peninsular Malaysia.
    Yunus NM; Johan MF; Ali Nagi Al-Jamal H; Husin A; Hussein AR; Hassan R
    Asian Pac J Cancer Prev; 2015; 16(12):4869-72. PubMed ID: 26163606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FLT3 inhibitors in AML: are we there yet?
    Sudhindra A; Smith CC
    Curr Hematol Malig Rep; 2014 Jun; 9(2):174-85. PubMed ID: 24682858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection the Frequency and Characteristics of FLT3 Internal Tandem Duplication Mutations by Capillary Electrophoresis Assay and Next-Generation Sequencing in.
    Ma L; Cao Y; Jiang Y; Cong X; Lu S; Shen J; Liu Q; Han C; Zhan Y; Cao Y
    Clin Lab; 2016 Oct; 62(10):2065-2072. PubMed ID: 28164543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.